SEARCH:   Advanced

Prepublished online as a Blood First Edition Paper on October 24, 2002; DOI 10.1182/blood-2002-07-2341. This Article Full Text (PDF) All Versions of this Article: 2002-07-2341v1 101/5/1981    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Reeder, T. L Articles by Tefferi, A. Search for Related Content PubMed PubMed Citation Articles by Reeder, T. L Articles by Tefferi, A. Social Bookmarking                   What's this? Submitted August 2, 2002 Accepted October 11, 2002 Both B and T lymphocytes may be clonally involved in myelofibrosis with myeloid metaplasia Terra L Reeder, Richard J Bailey, Gordon W Dewald, and Ayalew Tefferi* Department of Hematology and Internal Medicine, Mayo Clinic, Rochester, MN, USA Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA * Corresponding author; email: tefferi.ayalew{at}mayo.edu. A combination of magnetic cell sorting (MACS) and fluorescent in situ hybridization (FISH) techniques was used to detect clonal cytogenetic markers in different myeloid and lymphoid cell types of the peripheral blood from 4 patients with myelofibrosis with myeloid metaplasia (MMM) that was associated with either a 13q- or a 20q- karyotypic abnormality. Interphase cytogenetics studies demonstrated abnormal clonal FISH signal patterns in neutrophil, myeloid, erythroid, megakaryocyte, B and T cell preparations in 3 of the 4 patients. In one patient, FISH results were within normal limits in T cells and slightly abnormal in B cells. In general, the percentage of abnormal nuclei was variable in both lymphocyte populations, but always higher in B compared to T lymphocytes. The current study provides direct evidence for the clonal involvement of both B and T lymphocytes in MMM. A larger study is needed to clarify the relevance of the observed inter-patient heterogeneity in clonal constitution. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: A. M. Vannucchi, P. Guglielmelli, and A. Tefferi Advances in Understanding and Management of Myeloproliferative Neoplasms CA Cancer J Clin, May 1, 2009; 59(3): 171 - 191. [Abstract] [Full Text] [PDF] J.-J. Lataillade, O. Pierre-Louis, H. C. Hasselbalch, G. Uzan, C. Jasmin, M.-C. Martyre, M.-C. Le Bousse-Kerdiles, and on behalf of the French INSERM and the European EU Does primary myelofibrosis involve a defective stem cell niche? From concept to evidence Blood, October 15, 2008; 112(8): 3026 - 3035. [Abstract] [Full Text] [PDF] C. Vener, N. S. Fracchiolla, U. Gianelli, R. Calori, F. Radaelli, A. Iurlo, S. Caberlon, G. Gerli, L. Boiocchi, and G. L. Deliliers Prognostic implications of the European consensus for grading of bone marrow fibrosis in chronic idiopathic myelofibrosis Blood, February 15, 2008; 111(4): 1862 - 1865. [Abstract] [Full Text] [PDF] O. Wagner-Ballon, D. F. Pisani, T. Gastinne, M. Tulliez, R. Chaligne, C. Lacout, F. Aurade, J.-L. Villeval, P. Gonin, W. Vainchenker, et al. Proteasome inhibitor bortezomib impairs both myelofibrosis and osteosclerosis induced by high thrombopoietin levels in mice Blood, July 1, 2007; 110(1): 345 - 353. [Abstract] [Full Text] [PDF] A. Tefferi Primary myelofibrosis and its paraneoplastic stromal effects Haematologica, May 1, 2007; 92(5): 577 - 579. [Full Text] [PDF] D. P. Steensma and R. E. Richard Myeloproliferative disorders ASH Self-Assessment Program, January 1, 2007; 2007(1): 172 - 227. [Full Text] [PDF] T. Ishii, E. Bruno, R. Hoffman, and M. Xu Involvement of various hematopoietic-cell lineages by the JAK2V617F mutation in polycythemia vera Blood, November 1, 2006; 108(9): 3128 - 3134. [Abstract] [Full Text] [PDF] D. P. Steensma JAK2 V617F in Myeloid Disorders: Molecular Diagnostic Techniques and Their Clinical Utility: A Paper from the 2005 William Beaumont Hospital Symposium on Molecular Pathology J. Mol. Diagn., September 1, 2006; 8(4): 397 - 411. [Abstract] [Full Text] [PDF] C. Arana-Yi, A. Quintas-Cardama, F. Giles, D. Thomas, A. Carrasco-Yalan, J. Cortes, H. Kantarjian, and S. Verstovsek Advances in the Therapy of Chronic Idiopathic Myelofibrosis Oncologist, September 1, 2006; 11(8): 929 - 943. [Abstract] [Full Text] [PDF] A. Tefferi, G. Barosi, R. A. Mesa, F. Cervantes, H. J. Deeg, J. T. Reilly, S. Verstovsek, B. Dupriez, R. T. Silver, O. Odenike, et al. International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT) Blood, September 1, 2006; 108(5): 1497 - 1503. [Abstract] [Full Text] [PDF] O. Wagner-Ballon, H. Chagraoui, E. Prina, M. Tulliez, G. Milon, H. Raslova, J.-L. Villeval, W. Vainchenker, and S. Giraudier Monocyte/Macrophage Dysfunctions Do Not Impair the Promotion of Myelofibrosis by High Levels of Thrombopoietin. J. Immunol., June 1, 2006; 176(11): 6425 - 6433. [Abstract] [Full Text] [PDF] A. P. Wolanskyj, S. M. Schwager, R. F. McClure, D. R. Larson, and A. Tefferi Essential Thrombocythemia Beyond the First Decade: Life Expectancy, Long-term Complication Rates, and Prognostic Factors Mayo Clin. Proc., February 1, 2006; 81(2): 159 - 166. [Abstract] [Full Text] [PDF] A. Tefferi Pathogenesis of Myelofibrosis With Myeloid Metaplasia J. Clin. Oncol., November 20, 2005; 23(33): 8520 - 8530. [Abstract] [Full Text] [PDF] A. Tefferi and D. G. Gilliland The JAK2V617F Tyrosine Kinase Mutation in Myeloproliferative Disorders: Status Report and Immediate Implications for Disease Classification and Diagnosis Mayo Clin. Proc., July 1, 2005; 80(7): 947 - 958. [Abstract] [PDF] U. Popat, A. Frost, E. Liu, R. May, V. Reddy, A. Durett, and J. Prchal High Peripheral Blood CD34 Count in Patients with Idiopathic Myelofibrosis (IF) Is Not Due to Fibrosis and Altered Marrow Microenvironment. Blood (ASH Annual Meeting Abstracts), November 16, 2004; 104(11): 2439 - 2439. [Abstract] R. T. Silver Myelofibrosis: Thalidomide Finds a New Disease Mayo Clin. Proc., July 1, 2004; 79(7): 857 - 858. [PDF] S. O'Brien, A. Tefferi, and P. Valent Chronic Myelogenous Leukemia and Myeloproliferative Disease Hematology, January 1, 2004; 2004(1): 146 - 162. [Abstract] [Full Text] [PDF] C. Bilhou-Nabera, C. Brigaudeau, D. Clay, J. Andrieux, J.-L. Lai, D. Brouty-Boye, C. Vignon, M.-J. Gharbi, M.-C. Le Bousse-Kerdiles, and V. Praloran Does cytogenetic mosaicism in CD34+CD38low cells reflect the persistence of normal primitive hematopoietic progenitors in myeloid metaplasia with myelofibrosis? Blood, August 15, 2003; 102(4): 1551 - 1552. [Full Text] [PDF] A. Tefferi The Forgotten Myeloproliferative Disorder: Myeloid Metaplasia Oncologist, June 1, 2003; 8(3): 225 - 231. [Abstract] [Full Text] [PDF] J. L. Spivak, G. Barosi, G. Tognoni, T. Barbui, G. Finazzi, R. Marchioli, and M. Marchetti Chronic Myeloproliferative Disorders Hematology, January 1, 2003; 2003(1): 200 - 224. [Abstract] [Full Text] [PDF]

	Copyright © 2002 by American Society of Hematology         Online ISSN: 1528-0020